2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. URAT1
  5. URAT1 Inhibitor

URAT1 Inhibitor

URAT1 Inhibitors (35):

Cat. No. Product Name Effect Purity
  • HY-101439
    JTT-552
    		Inhibitor
    JTT-552 is a compound targeting URAT1 with activity in inhibiting hyperuricemia and gout.
  • HY-162829
    hURAT1 inhibitor 1
    		Inhibitor
    hURAT1 inhibitor 1 (compound 27b) is an isomarine-based, orally active dual hURAT1/GLUT9 inhibitor with IC50s of 0.16 μM and 4.47 μM, respectively, and has anti-hyperuricemia effects. hURAT1 inhibitor 1 showed significant uric acid-lowering activity in a hyperuricemia mouse model (10 mg/kg dose). hURAT1 inhibitor 1 had no significant in vitro cytotoxicity or in vivo hepatotoxicity and showed good PK characteristics.
  • HY-153970
    URAT1 inhibitor 7
    		Inhibitor
    URAT1 inhibitor 7 (compound 10f) is a potent URAT1 inhibitor, with an IC50 of 12 nM. URAT1 inhibitor 7 exhibits microsomal stability (HLM <13 µL/min/mg). URAT1 inhibitor 7 also inhibits CYP2C9, with an IC50 of 4.2 μM. URAT1 inhibitor 7 can be used for gout research.
  • HY-161523
    XOR/URAT1-IN-1
    		Inhibitor
    XOR/URAT1-IN-1 (Compound II15) is a dual inhibitor for xanthine oxidoreductase (XOR) and uric acid transporter 1 (URAT1), with IC50 of 6 nM and 12.9 μM. XOR/URAT1-IN-1 lowers the levels of uric acid in Potassium oxonate (HY-17511)/Hypoxanthine (HY-N0091)-induced acute hyperuricemia mouse model.
  • HY-152033
    URAT1 inhibitor 4
    		Inhibitor
    URAT1 inhibitor 4, a Lesinurad derivative, is a potent and orally active URAT1 inhibitor with an IC50 of 7.56 μM. URAT1 inhibitor 4 has higher in vivo urate-lowering efficacy than Lesinurad (HY-15258).
  • HY-163431
    URAT1 inhibitor 10
    		Inhibitor
    URAT1 inhibitor 10 (Compound 23a) is a URAT1 inhibitor. URAT1 inhibitor 10 has oral efficacy and low cytotoxicity. URAT1 inhibitor 10 has high selectivity for OAT1 .
  • HY-143906
    URAT1 inhibitor 2
    		Inhibitor
    URAT1 inhibitor 2 is an orally active and potent URAT1 and CYP isozyme inhibitor, with IC50 values of 1.36 μM, 16.97 μM, 5.22 μM for URAT1-mediated 14C-UA uptake, CYP1A2 and CYP2C9, respectively. URAT1 inhibitor 2 is a promising agent candidate in the study of hyperuricemia and gout.
  • HY-116694
    Digallic acid
    		Inhibitor
    Digallic acid is an antioxidant, antimutagenic, antigenotoxic, and anti-hyperuricemic compound. Digallic acid is a reverse transcriptase and XOD, URAT1 (IC50: 5.34 μM) inhibitor. Digallic acid scavenges DPPH· and O2·− radicals. Digallic acid induces apoptosis. Digallic acid can be isolated from the fruits of Pistascia lentiscus.
  • HY-153706
    URAT1 inhibitor 5
    		Inhibitor
    URAT1 inhibitor 5 (compound 16) is a potent URAT1 inhibitor. URAT1 inhibitor 5 can be used in research of hyperuricemia.
  • HY-160265
    URAT1 inhibitor 9
    		Inhibitor
    URAT1 inhibitor 9 (Compound 24) is an URAT1 inhibitor that can be used in the study of gout or hyperuricemia.
  • HY-15258S1
    Lesinurad-d4
    		Inhibitor
    Lesinurad-d4 (RDEA594-d4) is deuterium labeled Lesinurad. Lesinurad is a URAT1 and OAT inhibitor, is determined to be a substrate for the kidney transporters OAT1 and OAT3 with Km values of 0.85 and 2 μM, respectively.
  • HY-168740
    URAT1 inhibitor 11
    		Inhibitor
    URAT1 inhibitor 11 (Compound 7) is a URAT1 inhibitor with an IC50 value of 0.18 μM. URAT1 inhibitor 11 exhibits potent hypouricemic effects in hyperuricemic zebrafish induced by Potassium oxonate (HY-17511) and Xanthine sodium salt (HY-W017389).
  • HY-159581
    URAT1&XO inhibitor 3
    		Inhibitor
    URAT1&XO inhibitor 3 (compound 27) is an orally active anti-gout agent targeting XO (IC50: 35 nM) and URAT1 (IC50: 31 nM). URAT1&XO inhibitor 3 has good pharmacological and pharmacokinetic (PK) characteristics and in vivo safety.
  • HY-111345A
    Epaminurad hydrochloride
    		Inhibitor
    Epaminurad (UR-1102) hydrochloride is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a Ki of 0.057 μM. Epaminurad hydrochloride quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad hydrochloride is a uricosuric agent. Epaminurad hydrochloride can be used for gout and hyperuricemia research.
  • HY-W011711R
    Benzarone (Standard)
    		Inhibitor
    Benzarone (Standard) is the analytical standard of Benzarone. This product is intended for research and analytical applications. Benzarone (Fragivix) is a potent human uric acid transporter 1 (hURAT1) inhibitor, with an IC50 of 2.8 μM in oocyte. Benzarone could lower uric acid serum levels.